Published February 23, 2021 | Version v1
Journal article Open

Effect of Mastiha supplementation on NAFLD: The MAST4HEALTH randomised, controlled trial

Creators

  • 1. Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, Greece
  • 2. William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.
  • 3. Perspectum Ltd, Oxford, UK
  • 4. University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
  • 5. Sequencing and Bioinformatics Service, Fundació per al Foment de la Investigació Sanitària i Biomèdica de la Comunitat Valenciana (FISABIO-Salut Pública), Avda. Catalunya 21, València 46020, Spain and CIBER en Epidemiología y Salud Pública, Av. Monforte de Lemos 3-5, Madrid 28029, Spain.
  • 6. CIBER en Epidemiología y Salud Pública, Av. Monforte de Lemos 3-5, Madrid 28029, Spain and Joint Research Unit in Genomics and Health, Fundació per al Foment de la Investigació Sanitària i Biomèdica de la Comunitat Valenciana (FISABIO) and Institut de Biologia Integrativa de Sistemes (Universitat de València / Consejo Superior de Investigaciones Científicas), Avda. Catalunya 21, València 46020, Spain.
  • 7. UMR INSERM U1122; IGE-PCV, University of Loraine, Nancy, France
  • 8. Biotechvana, Parc Científic, Universitat de València, Paterna, Valencia, Spain
  • 9. University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia and Centre for Imaging Diagnostics, Oncology Insitute of Vojvodina, Sremska Kamenica, Serbia
  • 10. Division of Pharmacognosy and Natural Products Chemistry, Department of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece
  • 11. Sanofi Research and Development, Industriepark Hoechst, D-65926 Frankfurt, Germany and Institute of Experimental and Clinical Pharmacology and Toxicology, Medical Faculty Mannheim, University of Heidelberg, D-68169 Mannheim, Germany and Fraunhofer Institute for Molecular Biology and Applied Ecology, Division of Translational Medicine and Pharmacology, D-65926 Frankfurt, Germany
  • 12. Randox Laboratories Limited, Crumlin, Co. Antrim, Northern Ireland, UK
  • 13. Marascio Fernando, Intervideo, 88100 Catanzaro CZ, Italy
  • 14. Biotechvana, Parc Científic, Universitat de València, Paterna, Valencia, Spain and Facultad de Ciencias de la Salud, Universidad San Jorge, 50830, Zaragoza, Spain
  • 15. Chios Mastic Gum Growers Association, Chios, Greece
  • 16. Department of Informatics and Telematics, Harokopio University, Athens, Greece
  • 17. Department of Food Technology, Faculty of Technology Zvornik, University of East Sarajevo, 75400 Zvornik, Bosnia and Herzegovina.
  • 18. University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia and Clinic for Endocrinology,Diabetes and Metabolic Diseases, Clinical Centre of Vojvodina, Novi Sad, Serbia
  • 19. Division of Hepatology and Gastroenterology, Niguarda Ca' Grande Hospital Milan, Italy
  • 20. Institute of Clinical Physiology, CNR, Milan, Italy
  • 21. Cardiometabolic Risk Unit, Institute of Clinical Physiology, CNR, Pisa, Italy
  • 22. William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK and Centre for Genomic Health, Life Sciences, Queen Mary University of London, London, United Kingdom
  • 23. Institute of Clinical Physiology, CNR, Milan, Italy and Cardiometabolic Risk Unit, Institute of Clinical Physiology, CNR, Pisa, Italy

Description

NAFLD is an emerging public health issue globally and its prevalence is consistently increasing. Since there is no approved therapy for this liver disease and given that pharmacological treatment will be approved only for NASH, we wanted to investigate if Mastiha could be a non-pharmacological modulator of NAFLD markers.

Mastiha, has been shown to possess antioxidant/anti- inflammatory and lipid lowering properties and could have beneficial effects on hepatic and systemic parameters in subjects with NAFLD. To this aim we designed, MAST4HEALTH, a Marie Sklodowska-Curie Actions (MSCA) Research and Innovation Staff Exchange (RISE) program under the EU Horizon 2020 framework. MAST4HEALTH is a multicenter randomized double blind placebo controlled clinical trial to test Mastiha’s effectiveness as new non-pharmacologic strategy for NAFLD treatment (NCT03135873).

After 6-months of Mastiha supplementation, we observed a significant improvement on microbiota dysbiosis and lipid metabolite levels in patients with NAFLD. Among  severely obese patients, Mastiha also reduced markers of liver fibrosis (as assessed via MRI).

This is the pre-peer reviewed version which has been published in final form at 10.1002/mnfr.202001178. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.

Files

Figure1.tif

Files (13.9 MB)

Name Size Download all
md5:48ddc9a9387911997e641b19f89e64fb
9.7 MB Preview Download
md5:c67a4517b15c404f66b113f98879573f
924.3 kB Preview Download
md5:edb9802039b47383192a5ffe5a0889ae
924.3 kB Preview Download
md5:77bea2b066d1aad69a698d7be95be5e7
90.6 kB Download
md5:da2d9d717048e5aebe553789f6551a30
30.0 kB Download
md5:c0008abad9672759161d45430961d8ed
2.2 MB Download

Additional details

Funding

MAST4HEALTH – Mastiha treatment for healthy obese with NAFLD diagnosis (MAST4HEALTH). 691042
European Commission